Pliant slumps on decision to pause lung disease drug trial

Shares in Pliant plunged after the US biotech revealed that a safety signal led it to pause a trial of its idiopathic pulmonary fibrosis drug.

Pliant seeks $250m offering on lung fibrosis data

Buoyed by encouraging mid-stage clinical results for its idiopathic pulmonary fibrosis therapy bexotegrast, Pliant Therapeutics filed a $175million public offering, and then swiftly raised

Novartis takes $80M punt on early-stage NASH drug from Plian...